MethylGene Inc MYLGF

celgene

[noGnoG8]

Cancer Sci. 2011 Jun;102(6):1201-7. doi: 10.1111/j.1349-7006.2011.01921.x. Epub 2011 Apr 18.

Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.

Sung V, Richard N, Brady H, Maier A, Kelter G, Heise C.

Source

Celgene, San Francisco, California, USA. [e-mail]

Abstract

Histone deacetylase inhibitors are a group of recently developed compounds that modulate cell growth and survival. We evaluated the effects of the histone deacetylase inhibitor MGCD0103 on growth of pancreatic carcinoma models following single agent treatment and in combination with gemcitabine. MGCD0103 inhibited tumor cell growth and acted synergistically with gemcitabine to enhance its cytotoxic effects. Gene expression analysis identified the cell cycle pathway as one of the most highly modulated gene groups. Our data suggest that MGCD0103 + gemcitabine might be an effective treatment for gemcitabine-refractory pancreatic cancer.

© 2011 Japanese Cancer Association.